Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 appendix a supplementary data to this article can be found online at https://doi org/10 1016/j euros2023 03 001 ."

"

 Financial disclosures: Dominik Menges certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Aurelius Omlin has received institutional fees for an advisory role for Astellas, AstraZeneca, Bayer, Janssen, Molecular Partners, MSD, Pfizer, Roche, and Sanofi Aventis, personal fees for an advisory role for Astellas, AstraZeneca, Bayer, Janssen, Merck, MSD, and Novartis, institutional research support from Teva and Janssen, and travel support from Astellas, Bayer, Janssen, and Sanofi Aventis, and participates in speaker bureaus for Astellas, Bayer, and Janssen. Richard Cathomas has acted in an advisory role for Astellas, AstraZeneca, Bayer, BMS, Debiopharm, Ipsen, Merck, MSD, Janssen, Pfizer, Roche, and Sanofi, and has received honoraria from Astellas, BMS, and Janssen. Stefanie Fischer has received institutional fees for an advisory role for Ipsen and for speaker bureau participation for Janssen. Christian Rothermundt has received institutional fees for a consulting/advisory role for Bayer (Schweiz), Bristol-Myers Squibb, Ipsen, MSD Oncology, and Pfizer, personal fees for a consulting/advisory role for Merck (Schweiz), travel expenses from PharmaMar, and institutional research funding from Astellas. Lukas Prause has a compensated advisory role for Bayer and has received travel support from Astellas. Alix O’Meara Stern has received institutional fees for an advisory role for Takeda, AbbVie, Novartis, and Bayer, and participates in a speaker bureau for Incyte. Max Lippuner is a patient representative and acting president of Europa Uomo Switzerland, which received project-connected financial support from AbbVie, Amgen (Schweiz), Astellas, AstraZeneca, Bayer (Schweiz), Debiopharm, Janssen-Cilag, MediService, MSD International, Myriad Genetics, Sanofi-Aventis (Schweiz), and Sanofi Genzyme. The remaining authors have nothing to disclose. Financial disclosures:"

"

Funding/Support and role of the sponsor: This study was funded by the Swiss Cancer Research Foundation (Stiftung Krebsforschung Schweiz; grant no. HSR-4950-11-2019) and the Swiss Cancer Foundation. The salary of Dominik Menges was covered by a fellowship from the Béatrice Ederer-Weber Foundation. The funding bodies had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; the decision to publish; or preparation, review, or approval of the manuscript. 

Acknowledgments: We thank the LINK Institute for their professional support in realizing this study and in recruiting study participants from the general population. We also thank Europa Uomo Switzerland, the Swiss Cancer League (Krebsliga Schweiz), and EUPATI Switzerland for their support in establishing important links to ensure patient involvement and feedback in this research project. In addition, we thank Dr. Silke Gillessen and Dr. Ursula M. Vogl for their expert input on the study design and implementation of the main survey. Furthermore, we thank Karin Haefeli and Gabriela Manetsch-Dalla Torre for their administrative support at the recruiting study centers, and Sonja Rüegg for her administrative support at the coordinating study center. Finally, we thank all the study participants for their valuable time and support of this research project."